{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T21:38:34Z","timestamp":1792532314430,"version":"4.5.0"},"reference-count":84,"publisher":"Elsevier BV","issue":"4","content-domain":{"domain":["bloodreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.blre.2013.06.002","type":"journal-article","created":{"date-parts":[[2013,6,28]],"date-time":"2013-06-28T21:00:41Z","timestamp":1372453241000},"page":"179-184","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":128,"title":["Hemophilia A in the third millennium"],"prefix":"10.1016","volume":"27","author":[{"given":"Massimo","family":"Franchini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Mannuccio","family":"Mannucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2013.06.002_bb0005","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJM200106073442307","article-title":"The hemophilias \u2014 from royal genes to gene therapy","volume":"344","author":"Mannucci","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2013.06.002_bb0010","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/S0140-6736(03)13405-8","article-title":"Hemophilias A and B","volume":"361","author":"Bolton-Maggs","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2013.06.002_bb0015","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1056\/NEJM199401063300108","volume":"330","author":"Hoyer","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2013.06.002_bb0020","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(11)61139-2","article-title":"Modern haemophilia care","volume":"379","author":"Berntorp","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2013.06.002_bb0025","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1055\/s-0031-1297164","article-title":"Pediatric hemophilia: a review","volume":"37","author":"Kulkarni","year":"2011","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.blre.2013.06.002_bb0030","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1055\/s-2003-37935","article-title":"Structure and function of the FVIII gene and protein","volume":"29","author":"Thompson","year":"2003","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.blre.2013.06.002_bb0035","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1055\/s-2001-16885","article-title":"Molecular biology of blood coagulation","volume":"27","author":"Oldenburg","year":"2001","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.blre.2013.06.002_bb0040","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1055\/s-0031-1300953","article-title":"Role of molecular genetics in hemophilia: from diagnosis to therapy","volume":"38","author":"Jayandharan","year":"2012","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.blre.2013.06.002_bb0045","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1182\/blood-2011-09-379453","article-title":"F8 gene mutation type and inhibitor development in patients with severe hemophilia A: a systematic review and meta-analysis","volume":"119","author":"Gouw","year":"2012","journal-title":"Blood"},{"issue":"Suppl. 3","key":"10.1016\/j.blre.2013.06.002_bb0050","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1365-2516.2006.01268.x","article-title":"Pathogenesis of hemophilic arthropathy","volume":"12","author":"Roosendaal","year":"2006","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2013.06.002_bb0055","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1365-2141.2007.06949.x","article-title":"Intracranial hemorrhage in haemophilia A and B","volume":"140","author":"Ljung","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2013.06.002_bb0060","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2516.2011.02611.x","article-title":"Italian Association of Hemophilia Centers. Intracranial hemorrhage in the Italian population of hemophilia patients with and without inhibitors","volume":"18","author":"Zanon","year":"2012","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2013.06.002_bb0065","first-page":"178","article-title":"The modern treatment of haemophilia: a narrative review","volume":"11","author":"Franchini","year":"2012","journal-title":"Blood Transfus"},{"key":"10.1016\/j.blre.2013.06.002_bb0070","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1750-1172-7-24","article-title":"Past, present and future of hemophilia treatment: a narrative review","volume":"7","author":"Franchini","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.blre.2013.06.002_bb0075","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1046\/j.1538-7836.2003.00262.x","article-title":"Hemophilia: treatment options on the twenty-first century","volume":"1","author":"Mannucci","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"Suppl. 3","key":"10.1016\/j.blre.2013.06.002_bb0080","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1365-2516.2008.01708.x","article-title":"Back to the future: a recent history of haemophilia treatment","volume":"14","author":"Mannucci","year":"2008","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2013.06.002_bb0085","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1056\/NEJM198901193200307","article-title":"Use of recombinant antihemophilic factor in the treatment of two patients with classic hemophilia","volume":"320","author":"White","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2013.06.002_bb0090","first-page":"537","article-title":"Recombinant FVIII products","volume":"36","author":"Franchini","year":"2010","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.blre.2013.06.002_bb0095","series-title":"Registry of clotting factor concentrates","author":"Brooker","year":"2012"},{"key":"10.1016\/j.blre.2013.06.002_bb0100","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1182\/blood.V90.7.2515","article-title":"Desmopressin (DDAVP) in the treatment of bleeding disorders: the first twenty years","volume":"90","author":"Mannucci","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.06.002_bb0105","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/ajh.20940","article-title":"The use of desmopressin as a hemostatic agent","volume":"82","author":"Franchini","year":"2007","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2013.06.002_bb0110","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1055\/s-2003-37944","article-title":"Desmopressin in mild hemophilia A: indications, limitations, efficacy, and safety","volume":"29","author":"Lethagen","year":"2003","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.blre.2013.06.002_bb0115","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1538-7836.2009.03717.x","article-title":"Mild hemophilia A","volume":"8","author":"Franchini","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2013.06.002_bb0120","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/01.mph.0000168728.49519.4a","article-title":"DDAVP-induced hyponatremia in young children","volume":"27","author":"Das","year":"2005","journal-title":"J Pediatr Hematol Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2013.06.002_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2516.9.s1.17.x","article-title":"Consensus perspectives on prophylaxis therapy for haemophilia: summary statement","volume":"9","author":"Berntorp","year":"2003","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2013.06.002_bb0130","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1160\/TH08-07-0483","article-title":"Prophylaxis in people with hemophilia","volume":"101","author":"Coppola","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2013.06.002_bb0135","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1055\/s-0031-1300954","article-title":"Prophylaxis in children with hemophilia: evidence-based achievements, old and new challenges","volume":"38","author":"Coppola","year":"2012","journal-title":"Semin Thromb Hemost"},{"issue":"3 Suppl. 2","key":"10.1016\/j.blre.2013.06.002_bb0140","first-page":"16","article-title":"Experience with prophylaxis in Sweden","volume":"30","author":"Nilsson","year":"1993","journal-title":"Semin Hematol"},{"key":"10.1016\/j.blre.2013.06.002_bb0145","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1365-2141.2010.08139.x","volume":"149","author":"Richards","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2013.06.002_bb0150","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2013.06.002_bb0155","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/j.1538-7836.2011.04214.x","article-title":"A randomized clinical trial of prophylaxis in children with haemophilia A (the ESPRIT study)","volume":"9","author":"Gringeri","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2013.06.002_bb0160","first-page":"CD003429","article-title":"Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B","volume":"9","author":"Iorio","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl. 3","key":"10.1016\/j.blre.2013.06.002_bb0165","first-page":"160","article-title":"Prophylaxis versus on-demand therapy through economic report (POTTER) study: preliminary data from the final five-year analysis","volume":"18","author":"Tagliaferri","year":"2012","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2013.06.002_bb0170","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1538-7836.2011.04611.x","article-title":"A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management","volume":"10","author":"Valentino","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2013.06.002_bb0175","doi-asserted-by":"crossref","DOI":"10.1111\/jth.12202","article-title":"Randomized, controlled, parallel-group trial of routine prophylaxis versus on-demand treatment with rFVIII-FS in adults with severe hemophilia A (SPINART)","author":"Manco-Johnson","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2013.06.002_bb0180","first-page":"123","article-title":"Prophylaxis for adults with haemophilia: towards a personalized approach?","volume":"10","author":"Franchini","year":"2012","journal-title":"Blood Transfus"},{"key":"10.1016\/j.blre.2013.06.002_bb0185","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1002\/pbc.24340","article-title":"Hemophilia and prophylaxis","volume":"60","author":"Ljung","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.blre.2013.06.002_bb0190","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1055\/s-0029-1245113","article-title":"Recent improvements in the clinical treatment of coagulation factor inhibitors","volume":"35","author":"Franchini","year":"2009","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.blre.2013.06.002_bb0195","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1365-2125.2010.03899.x","article-title":"Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice","volume":"72","author":"Franchini","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.blre.2013.06.002_bb0200","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1182\/blood-2003-03-0941","article-title":"Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group","volume":"102","author":"Gringeri","year":"2003","journal-title":"Blood"},{"issue":"2 Suppl. 4","key":"10.1016\/j.blre.2013.06.002_bb0205","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1053\/j.seminhematol.2006.03.006","article-title":"Overview of inhibitors","volume":"43","author":"Astermark","year":"2006","journal-title":"Semin Hematol"},{"key":"10.1016\/j.blre.2013.06.002_bb0210","doi-asserted-by":"crossref","DOI":"10.1179\/1607845412Y.0000000057","article-title":"Alloantibodies in previously untreated hemophilia A patients: the role of environmental factors","author":"Franchini","year":"2013","journal-title":"Hematology"},{"key":"10.1016\/j.blre.2013.06.002_bb0215","first-page":"288","article-title":"Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasma-derived is better","volume":"8","author":"Mannucci","year":"2010","journal-title":"Blood Transfus"},{"key":"10.1016\/j.blre.2013.06.002_bb0220","first-page":"292","article-title":"Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: recombinant is better","volume":"8","author":"Franchini","year":"2010","journal-title":"Blood Transfus"},{"key":"10.1016\/j.blre.2013.06.002_bb0225","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1160\/TH10-03-0151","article-title":"Von Willebrand factor-containing factor VIII concentrates and inhibitors in haemophilia A. A critical literature review","volume":"104","author":"Franchini","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2013.06.002_bb0230","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1111\/j.1538-7836.2012.04902.x","article-title":"Factor VIII inhibitors: von Willebrand factor makes a difference in vitro and in vivo","volume":"10","author":"Shi","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2013.06.002_bb0235","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1111\/j.1538-7836.2012.04922.x","article-title":"Von Willebrand factor: factor VIII protector and friend","volume":"10","author":"Ragni","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2013.06.002_bb0240","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1046\/j.1365-2516.2003.00780.x","article-title":"The epidemiology of inhibitors in haemophilia A: a systematic review","volume":"9","author":"Wight","year":"2003","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2013.06.002_bb0245","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/j.1538-7836.2010.03823.x","article-title":"Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review","volume":"8","author":"Iorio","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2013.06.002_bb0250","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.critrevonc.2011.01.002","article-title":"Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: a critical systematic review","volume":"81","author":"Franchini","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.blre.2013.06.002_bb0255","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1056\/NEJMoa1208024","article-title":"Factor VIII products and inhibitor development in severe hemophilia A","volume":"368","author":"Gouw","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2013.06.002_bb0260","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/hae.12149","article-title":"The Rodin (Research Of Determinants of INhibitor development among pups with haemophilia) study: the clinical conundrum from the perspective of haemophilia treaters","volume":"19","author":"Kessler","year":"2013","journal-title":"Haemophilia"},{"issue":"Suppl. 5","key":"10.1016\/j.blre.2013.06.002_bb0265","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1365-2516.2007.01580.x","article-title":"Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma-product exposed toddlers)","volume":"13","author":"Mannucci","year":"2007","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2013.06.002_bb0270","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1055\/s-0030-1255442","article-title":"Recombinant activated factor VII: mechanisms of action and current indications","volume":"36","author":"Franchini","year":"2010","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.blre.2013.06.002_bb0275","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1055\/s-0032-1309286","article-title":"FEIBA: a prohemostatic agent","volume":"38","author":"Cromwell","year":"2012","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.blre.2013.06.002_bb0280","article-title":"FEIBA versus Novo Seven in hemophilia patients with inhibitors","author":"Franchini","year":"2013","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.blre.2013.06.002_bb0285","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1538-7836.2006.01772.x","article-title":"A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors","volume":"4","author":"Santagostino","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2013.06.002_bb0290","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1160\/TH05-07-0510","article-title":"Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial","volume":"95","author":"Kavakli","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2013.06.002_bb0295","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1111\/j.1538-7836.2007.02663.x","article-title":"Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors","volume":"5","author":"Konkle","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2013.06.002_bb0300","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1056\/NEJMoa1104435","article-title":"Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors","volume":"365","author":"Leissinger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2013.06.002_bb0305","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/bjh.12028","article-title":"Immune tolerance in haemophilia: the long journey to the fork in the road","volume":"159","author":"DiMichele","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2013.06.002_bb0310","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11239-011-0624-3","article-title":"Immune tolerance induction for patients with severe hemophilia: a critical literature review","volume":"32","author":"Franchini","year":"2011","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.blre.2013.06.002_bb0315","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/bjh.12091","article-title":"UK Haemophilia Centre Doctors. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization","volume":"160","author":"Collins","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2013.06.002_bb0320","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1365-2141.2010.08263.x","article-title":"Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches","volume":"150","author":"Coppola","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2013.06.002_bb0325","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1182\/blood-2011-08-369132","article-title":"The principal results of the International Immune Tolerance Study: a randomized dose comparison","volume":"119","author":"Hay","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.06.002_bb0330","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1111\/j.1538-7836.2011.04493.x","article-title":"The use of a single von Willebrand factor-containing, plasma-derived FVIII product in hemophilia A immune tolerance induction: the US experience","volume":"9","author":"Kurth","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"Suppl. 2","key":"10.1016\/j.blre.2013.06.002_bb0335","first-page":"s14","article-title":"A role for von Willebrand factor in immune tolerance induction in patients with haemophilia A and inhibitors?","volume":"9","author":"Di Minno","year":"2011","journal-title":"Blood Transfus"},{"key":"10.1016\/j.blre.2013.06.002_bb0350","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1365-2516.2009.02188.x","article-title":"Italian Association of Hemophilia Centers. Mortality and causes of death in Italian persons with haemophilia, 1990\u20132007","volume":"16","author":"Tagliaferri","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2013.06.002_bb0355","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/j.1365-2141.2009.08005.x","article-title":"Co-morbidities and quality of life in elderly persons with haemophilia","volume":"148","author":"Franchini","year":"2010","journal-title":"Br J Haematol"},{"issue":"Suppl. 5","key":"10.1016\/j.blre.2013.06.002_bb0360","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1365-2516.2010.02287.x","article-title":"The challenge of an ageing haemophilic population","volume":"16","author":"Dolan","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2013.06.002_bb0365","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1538-7836.2011.04566.x","article-title":"Cancers in patients with hemophilia: a retrospective study from the Italian Association of Hemophilia Centers","volume":"10","author":"Tagliaferri","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2013.06.002_bb0370","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1182\/blood-2009-07-215665","article-title":"How I treat age-related morbidities in elderly persons with hemophilia","volume":"114","author":"Mannucci","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.06.002_bb0375","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1538-7836.2008.03201.x","article-title":"Cardiovascular disease in patients with hemophilia","volume":"7","author":"Tuinenburg","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2013.06.002_bb0380","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1055\/s-0030-1248728","article-title":"The management of cardiovascular diseases in patients with hemophilia","volume":"36","author":"Coppola","year":"2010","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.blre.2013.06.002_bb0385","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1538-7836.2009.03669.x","article-title":"Coronary atherosclerosis and cardiovascular mortality in hemophilia","volume":"8","author":"Foley","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2013.06.002_bb0390","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1538-7836.2011.04514.x","article-title":"Coronary artery calcification score and carotid intima\u2013media thickness in patients with hemophilia","volume":"10","author":"Zwiers","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2013.06.002_bb0395","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1600-0609.2012.01835.x","article-title":"History of non-fatal cardiovascular disease in a cohort of Dutch and British patients with haemophilia","volume":"89","author":"Van de Putte","year":"2012","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2013.06.002_bb0400","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/j.1538-7836.2009.03318.x","article-title":"Health status and quality of life of elderly persons with severe hemophilia born before the advent of modern replacement therapy","volume":"7","author":"Siboni","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2013.06.002_bb0405","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1002\/ajh.23146","article-title":"The hope and reality of long-acting hemophilia products","volume":"87","author":"Pipe","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2013.06.002_bb0430","doi-asserted-by":"crossref","DOI":"10.1517\/13543784.2013.798302","article-title":"Investigational drugs for coagulation disorders","author":"Mannucci","year":"2013","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.blre.2013.06.002_bb0410","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1182\/asheducation.V2012.1.362.3798344","article-title":"New challenges in hemophilia: long-term outcomes and complications","author":"Young","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.blre.2013.06.002_bb0415","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1182\/blood-2012-05-423210","article-title":"The gene therapy journey for hemophilia: are we there yet?","volume":"120","author":"High","year":"2012","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2013.06.002_bb0420","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1538-7836.2011.04369.x","article-title":"Gene therapy for haemophilia: a long and winding road","volume":"9","author":"High","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"365","key":"10.1016\/j.blre.2013.06.002_bb0425","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"1","author":"Nathwani","year":"2011","journal-title":"N Engl J Med"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X13000313?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X13000313?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T08:41:09Z","timestamp":1715589669000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X13000313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":84,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S0268960X13000313"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2013.06.002","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hemophilia A in the third millennium","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2013.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}